

SAHA Patient: IV vs ORAL (200 mg/dose)




FIG. 1

**Protocol 01-021 (ORAL SAHA) ARM A: SOLID
TUMOR PATIENTS Cohort I (200 mg/dose)**




FIG. 2

SAHA Patients: ORAL /Cohort I (200 mg/dose)




FIG 3

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort I (200 mg/dose)

6-OS-200
(12-13-01)





FIG. 4

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)
7-OS-400 8-OS-400



12/19/01




FIG. 5

SAHA Patients: ORAL/Cohort II (400 mg/dose)




FIG. 6

Protocol 01-021 (ORAL SAHA)
ARM A: SOLID TUMOR PATIENTS
Cohort IIa (400 mg/dose)





FIG. 7

SAHA Patients. ORAL/Cohort II (400 mg/dose)



12-OS-400

02/15/02




FIG. 8

Oral 200 mg vs. 400 mg (Fasting)




Figure 9A

Oral 200 mg vs. 400 mg (no-fasting)




Figure 9B

IV 200 mg VS. 400 mg





Figure 9C

Apparent Half-life of the Oral Dose




■=200 mg group (n=3-5); □=400 mg group (n=5-10)

3/4/2003

Figure 10

AUC of the Oral Dose



■ =200 mg group (n=3-5); □ =400 mg group (n=5-10)

3/4/2003

Figure 11

Bioavailability




Figure 12

CTCL Patient 001 (MID Anderson)

Baseline

After 1 week of SAHA





FIG. 13A

CONFIDENTIAL

ATON
P H A R M A

CTCL Patient 001 (MJD Anderson)

Baseline



After 1 Week of SAHA




FIG. 13B

CONFIDENTIAL

ATON
P H A R M A

CTCL Patient 008 (MID Anderson)

Baseline

After 8 weeks of SAHA





FIG. 13C

CTCL Patient 008 (MID Anderson)

Baseline



After 8 weeks of SAHA




FIG. 13D

CONFIDENTIAL

ATON
PHARM

Metastatic Laryngeal Cancer

Pre-treatment

After 8 weeks of
treatment




FIG. 14

ATON
P H A R M A

CONFIDENTIAL